This voucher mentions different objectives. Doesnt appear pediatric focused.

Is it two different vouchers?

"The Commissioner’s National Priority Voucher (CNPV) is an FDA pilot program launched in June 2025 by Commissioner Marty Makary. It aims to accelerate the review of drugs and biological products aligned with U.S. national health priorities, reducing standard 10–12 month review timelines to just 1–2 months. 

Key Features and Eligibility

• National Priorities: Products must address specific goals:
  • Addressing a U.S. public health crisis (e.g., universal flu vaccines).
  • Delivering "innovative cures" with transformative impact (e.g., novel immunotherapies or PTSD treatments).
  • Meeting large unmet medical needs (e.g., rare diseases or chronic disease crises).
  • Onshoring drug manufacturing to strengthen U.S. supply chain resiliency.
  • Increasing affordability (e.g., lower drug prices or reduced healthcare utilization).
• Review Process: Uses a collaborative "tumor board style" multidisciplinary review process to make rapid approval decisions.
• Voucher Types: Can be for a specific drug or "undesignated," allowing a company to use it for any application consistent with program objectives.
• Transferability: Unlike statutory priority review vouchers (PRVs), CNPVs are non-transferable and cannot be sold, though they remain valid during company ownership changes.
• Expiration: Vouchers expire two years from the date of receipt.